Tissue Repair Ltd (TRP.AX)
AUD 0.27
(0.0%)
AUD 0.27
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -16.44 Million AUD | 23.16% |
| 2023 | -21.39 Million AUD | 15.94% |
| 2022 | -25.45 Million AUD | -29.8% |
| 2021 | -19.61 Million AUD | -1610.18% |
| 2020 | -1.14 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -16.44 Million AUD | 14.65% |
| 2024 Q2 | -19.26 Million AUD | 0.0% |
| 2024 FY | -16.44 Million AUD | 23.16% |
| 2024 Q1 | -19.26 Million AUD | 24.32% |
| 2024 Q4 | -16.44 Million AUD | 0.0% |
| 2023 Q1 | -22.81 Million AUD | 10.38% |
| 2023 FY | -21.39 Million AUD | 15.94% |
| 2023 Q3 | -21.39 Million AUD | 6.21% |
| 2023 Q4 | -25.45 Million AUD | -18.97% |
| 2023 Q2 | -22.81 Million AUD | 0.0% |
| 2022 Q1 | -26.61 Million AUD | -9989.94% |
| 2022 FY | -25.45 Million AUD | -29.8% |
| 2022 Q4 | -25.45 Million AUD | 0.0% |
| 2022 Q3 | -25.45 Million AUD | 4.35% |
| 2022 Q2 | -26.61 Million AUD | 0.0% |
| 2021 Q3 | -263.76 Thousand AUD | 0.0% |
| 2021 FY | -19.61 Million AUD | -1610.18% |
| 2021 Q1 | 1.14 Million AUD | 0.0% |
| 2021 Q4 | -263.76 Thousand AUD | 0.0% |
| 2020 FY | -1.14 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 13.005% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -1574.059% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 424.452% |
| Biome Australia Limited | -1.56 Million AUD | -952.021% |
| Patrys Limited | -2.24 Million AUD | -633.759% |
| Orthocell Limited | -19.92 Million AUD | 17.484% |
| Imugene Limited | -91.56 Million AUD | 82.044% |
| Noxopharm Limited | -2.31 Million AUD | -608.688% |
| PYC Therapeutics Limited | -65.76 Million AUD | 74.999% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -438.521% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -61.778% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -159.985% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -164.947% |
| CSL Limited | 15.76 Billion AUD | 100.104% |
| Arovella Therapeutics Limited | -12.71 Million AUD | -29.31% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -2217.083% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 91.015% |
| Starpharma Holdings Limited | -19.83 Million AUD | 17.098% |
| Nanollose Limited | -96.22 Thousand AUD | -16986.049% |
| Memphasys Limited | 4.13 Million AUD | 497.571% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -172.877% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -231.865% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -801.576% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 79.269% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -1227.595% |
| Race Oncology Limited | -17.18 Million AUD | 4.35% |
| Nyrada Inc. | -4.76 Million AUD | -244.721% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 84.459% |
| Dimerix Limited | -21.99 Million AUD | 25.24% |
| PharmAust Limited | -9.71 Million AUD | -69.249% |
| Immutep Limited | -122.18 Million AUD | 86.545% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 87.956% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -31.741% |
| BTC Health Limited | -2.02 Million AUD | -713.046% |
| Acrux Limited | -1.45 Million AUD | -1027.644% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 3.82% |
| Biotron Limited | -386.06 Thousand AUD | -4158.589% |
| AdAlta Limited | -845.17 Thousand AUD | -1845.288% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 11.488% |
| Hexima Limited | -2.22 Million AUD | -638.521% |
| AnteoTech Limited | -5 Million AUD | -228.721% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 6.487% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -384.111% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -208.506% |
| Actinogen Medical Limited | -9.13 Million AUD | -80.044% |
| Immuron Limited | -11.48 Million AUD | -43.167% |
| Argenica Therapeutics Limited | -15.91 Million AUD | -3.321% |